- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07909239
LBBAP Versus ILR in Patients With New-Onset LBBB and Moderately Reduced LVEF After TAVI (LBB(AP)TAVI)
Comparison of Left Bundle Branch Area Pacing (LBB(AP)) and Implantable Loop Recorder (ILR) in Patients With New-onset Left Bundle Branch Block and Moderately Reduced LVEF After Transcatheter Aortic Valve Implantation (TAVI): A Randomized Multicenter Study.
Patients with new-onset complete LBBB (QRS > 120 ms, persisting > 24 h after TAVI) and moderately reduced LVEF (35-50%) will be screened in participating centers.
Eligible patients will be centrally randomized 1:1 (stratified by center and atrial fibrillation (yes/no)) to either:
- Experimental arm: Left bundle branch area pacing (LBB(AP)) with Biotronik pacemaker and dedicated conduction system pacing leads.
- Control arm: Implantable loop recorder (ILR, Biotronik BIOMONITOR IV) for rhythm monitoring.
The occurrence of the following events within 12 months of randomization will be evaluated: hospitalization for heart failure, syncope or hemodynamically significant dizziness, or high-grade atrioventricular conduction disturbance.
The impact of LBB(AP) compared to ILR monitoring will be evaluated at 6, 12, 24, and 36 months regarding: incidence of atrial fibrillation; incidence of non-sustained ventricular tachycardia; evolution of left ventricular ejection fraction; quality of life; hospitalizations; mortality; medico-economic outcomes; qccurrence of high-grade AV conduction disorders beyond 12 months; omplications related to pacemaker or ILR implantation; unscheduled pacemaker implantation in the ILR group.
Patients will be monitored following a regular schedule that includes clinical visits, transthoracic echocardiography , ECG, remote device monitoring, and EQ-5D at 6, 12, 24 and 36 months.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Lise Laclautre
- Número de teléfono: +33473754963
- Correo electrónico: promo_interne_drci@chu-clermontferrand.fr
Ubicaciones de estudio
-
-
-
Angers, Francia, 49000
- CHU d'Angers
-
Investigador principal:
- Antoine POIRIER
-
Clermont-Ferrand, Francia, 63000
- Chu Clermont Ferrand
-
Investigador principal:
- Romain ESCHALIER
-
Contacto:
- Lise Laclautre
- Correo electrónico: promo_interne_drci@chu-clermontferrand.fr
-
Dijon, Francia, 21000
- CHU de DIJON
-
Investigador principal:
- Fabien GARNIER
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Patients with new-onset complete left bundle branch block (LBBB) defined as QRS duration >120 ms, occurring after TAVI and persisting for >24 hours on ECG. New-onset complete LBBB will be confirmed by QRS duration >120 ms together with standard morphological criteria (broad, notched or slurred R waves in leads I, aVL, V5 and V6, with absence of Q waves in V5-V6), assessed by the site cardiologist and confirmed by the adjudication committee, in line with current ESC and ACC/AHA/HRS recommendations.
- Left ventricular ejection fraction (LVEF) between 35% and 50%, assessed within one month before TAVI, in a stable hemodynamic state.
- Patients implanted with a self-expanding or balloon-expandable valve.
- Age ≥ 18 years.
- TAVI procedure performed according to current ESC guidelines. The applicable reference is the 2025 ESC/EACTS Guidelines for the management of valvular heart disease (Praz, et al. Eur Heart J. (2025) 46, 4635-4736), or any subsequent official ESC update in force at the time of each patient's procedure.
- Life expectancy > 1 year.
- Affiliation to a social security scheme
- Written informed consent provided before study enrollment.
Exclusion Criteria:
- Permanent pacemaker implantation (PPI) before TAVI.
- Complete atrioventricular block after TAVI leading to immediate PPI.
- Permanent pacemaker implantation after TAVI for another indication (non-protocol).
- Pre-existing LBBB before TAVI.
- Trans-venous permanent pacemaker implantation: No superior vena cava access or mechanical tricuspid valve.
- Pregnancy or breastfeeding.
- No affiliation to a social security scheme.
- Refusal to participate or withdrawal of informed consent.
- Incapacity to consent.
- Adults under legal protection (trusteeship, guardianship, curatorship).
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Left bundle branch area pacing with pacemaker and conduction system pacing (AMVIA SKY DR-T device)
|
LBB(AP) procedure will be performed by experienced operators according international guidelines and expert consensus. The implantation technique will be those used routinely in these expert centers. The procedure will begin with a vein access (axillary, sub-clavian or cephalic). The atrial, if necessary, will be implanted as usual practice. LBB(AP) lead will be implanted as recommended. LBB(AP) positioning criteria, as described in reference clinical studies, will be checked in order to differentiate between LBB(AP) and deep septal pacing. |
|
Otro: Implantable loop recorder for rhythm monitoring (ILR, Biotronik BIOMONITOR IV Device)
Control arm |
ILR Procedure will be performed by experienced operators according international guidelines and expert consensus. The implantation technique will be those used routinely in these expert centers. The implanted device will be a Biomonitor IV (Biotronik, Berlin, Germany) and next generation if necessary. The implantable Loop Recorder is a single-lead ECG monitor of small size with long-term functionality (approximately 3 to 5 years). It is implanted under local anesthesia in the subcutaneous space of the left thoracic region (incision at the level of the 4th left intercostal space at a 45° angle). |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
The first occurrence of one of the following events : hospitalization for worsening heart failure, episode of syncope or dizziness, high-grade atrioventricular conduction disturbance)
Periodo de tiempo: From randomization to 12 follow up
|
The primary efficacy endpoint is a composite clinical outcome evaluated at 12 months after randomization, defined as the first occurrence of one of the following events:
The composite endpoint will be analyzed as time-to-event data with death considered as a competing risk. |
From randomization to 12 follow up
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Incidence of atrial fibrillation, ventricular tachycardia, non-sustained ventricular tachycardia
Periodo de tiempo: At 6,12, 24 and 36 months after randomization
|
At 6,12, 24 and 36 months after randomization
|
|
|
Evolution of LVEF
Periodo de tiempo: At 6,12, 24 and 36 months after randomization
|
Measurement of LVEF at inclusion and at each follow-up time point. The change in LVEF over time will be assessed relative to the date of inclusion and the preceding time point. |
At 6,12, 24 and 36 months after randomization
|
|
Evolution of Quality of life (EQ-5D)
Periodo de tiempo: At 6, 12, 24 and 36 months after randomization
|
Measurement of EQ-5D at inclusion and at each follow-up time point. The change in EQ-5D over time will be assessed relative to the date of inclusion and the preceding time point. |
At 6, 12, 24 and 36 months after randomization
|
|
Incidence of Hospitalizations (all-cause, cardiovascular, HF-related)
Periodo de tiempo: At 6, 12, 24 and 36 months after randomization
|
At 6, 12, 24 and 36 months after randomization
|
|
|
Incidence of Mortality (all-cause, cardiovascular, HF-related)
Periodo de tiempo: At 6, 12, 24 and 36 months after randomization
|
Measurement of the cumulative incidence of all-cause, cardiovascular, and heart failure-related mortality at 6, 12, 24, and 36 months after randomization, based on the occurrence and documented cause of death. |
At 6, 12, 24 and 36 months after randomization
|
|
Medico-economic evaluation
Periodo de tiempo: At 6, 12, 24 and 36 months after randomization
|
At 6, 12, 24 and 36 months after randomization
|
|
|
Complications related to pacemaker or ILR implantation
Periodo de tiempo: At 6, 12, 24 and 36 months after randomization
|
At 6, 12, 24 and 36 months after randomization
|
|
|
Unscheduled pacemaker implantation in the ILR group
Periodo de tiempo: At 6, 12, 24 and 36 months after randomization
|
At 6, 12, 24 and 36 months after randomization
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- RBHP 2025 ESCHALIER 2
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .